Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540941 | 0.83 | MAPK1 (0.61) | MAPK1HTTALDH1A1HSD17B10HCAR1 | |
| SCHEMBL27259717 | 0.82 | ESR1 (0.48) | MAPK1HTTPRMT5ALDH1A1HCAR1 | |
| SCHEMBL10231916 | 0.80 | MAPK1 (0.57) | MAPK1HTTALDH1A1HSD17B10HCAR1 | |
| SCHEMBL18923546 | 0.78 | HRH3 (0.57) | MAPK1HTTHSD17B10SMN1; SMN2ALOX12 | |
| SCHEMBL31258944 | 0.78 | HCAR1 (0.51) | HTTPRMT5ALDH1A1HSD17B10HCAR1 | |
| SCHEMBL11901796 | 0.77 | PRMT5 (0.44) | PRMT5 | |
| SCHEMBL12472460 | 0.77 | PRMT5 (0.44) | PRMT5 | |
| SCHEMBL21263258 | 0.75 | PRMT5 (0.66) | PRMT5ALDH1A1PSMB8SMN1; SMN2NPC1 | |
| SCHEMBL23652504 | 0.75 | HTT (0.41) | MAPK1HTTPRMT5ALDH1A1PSMB8 | |
| SCHEMBL9694239 | 0.73 | ALDH1A1 (0.65) | MAPK1HTTALDH1A1HSD17B10HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | claimed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | claimed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | claimed |
| EP-2044033-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009348-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | claimed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | claimed |
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-2044033-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009348-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | DDT, NIT2, PADI1 | MAPK1 3566/4885HTT 2283/4885PRMT5 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.